151P CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with doublet chemotherapy (Nab-PTX & S-1) and apatinib (anti-angiogenic TKI) for the first-line treatment of stage IV gastric cancer (GC)
Qian‐Li Xue(Johns Hopkins University), Han Liang(Sun Yat-sen University), Hong Liu(Tianjin Medical University Cancer Institute and Hospital), Lei Wu(First Affiliated Hospital of Jiangxi Medical College), B. Wang(Tianjin Medical University), Wenbai Huang(Tianjin Medical University Cancer Institute and Hospital), Hongjie Zhan, Y. Liu(Nanfang Hospital), B. Li(Tianjin Medical University Cancer Institute and Hospital), N. Liu(Tianjin Medical University Cancer Institute and Hospital), Xin Wang(Institute of Oceanology), Mingzhi Cai(Tianjin Medical University Cancer Institute and Hospital), Bin Ke(Tianjin Medical University Cancer Institute and Hospital), Yan Sun(Dongguan People’s Hospital), J. Deng(Tianjin Medical University Cancer Institute and Hospital), Xiumin Ding(Tianjin Medical University Cancer Institute and Hospital)
Cited by 3
Related Papers
Frailty in Older Adults: A Nationally Representative Profile in the United States
|The Journals of Gerontology Series A|2015|789
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Interventions for Frailty Among Older Adults With Cardiovascular Disease
|Journal of the American College of Cardiology|2022|393
Insulin-Like Growth Factor I and Interleukin-6 Contribute Synergistically to Disability and Mortality in Older Women
|The Journal of Clinical Endocrinology & Metabolism|2003|290
Simple Biologically Informed Inflammatory Index of Two Serum Cytokines Predicts 10 Year All-Cause Mortality in Older Adults
|The Journals of Gerontology Series A|2013|277